
TOKYO -- A cancer drug widely seen as a symbol of exorbitant health care costs is about to get cheaper in Japan, when the health ministry updates government-administered prescription drug prices for next fiscal year.
Government, which already halved Opdivo price, seeks more cost relief
TOKYO -- A cancer drug widely seen as a symbol of exorbitant health care costs is about to get cheaper in Japan, when the health ministry updates government-administered prescription drug prices for next fiscal year.
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.